Overview
- Beretta’s lawyers, following Friday’s refusal to lift Ruger’s poison pill, warned in a Tuesday letter that they may sue and confirmed an April 9 meeting in New York.
- Ruger is keeping a shareholder-rights plan adopted in October 2025 that lets it sell new shares at a 50% discount if any investor tops 10%, a move that would dilute Beretta.
- Beretta is offering $44.80 in cash per share to buy up to 20.05% of Ruger, which would lift its holding to about 30% in a deal worth roughly $130 million.
- Ruger accuses Beretta of a creeping takeover to gain influence without a full bid, while Beretta says it aims to act as a constructive strategic partner.
- The clash unfolds as Ruger’s revenue has fallen to about $535 million in 2024 from a 2021 peak and its market value has dropped sharply since 2021, sharpening the stakes for investors.